OQL033

OQL033 is an investigational small-molecule drug being developed by OnQuality Pharmaceuticals as a supportive care therapy to prevent or treat chemotherapy-induced hand-foot syndrome (palmar-plantar erythrodysesthesia), a painful cutaneous toxicity that commonly occurs with agents such as capecitabine and other fluoropyrimidines. Publicly available information on its precise molecular target and mechanism of action has not yet been disclosed, but OnQuality’s pipeline is focused on rationally designed agents that modulate specific pathways underlying cancer therapy–related toxicities, suggesting OQL033 is intended to act directly on the skin’s stress and repair signaling involved in chemotherapy-induced damage rather than on tumor cells themselves. The program is positioned as a non-oncology supportive care intervention to improve tolerability and continuity of cytotoxic chemotherapy regimens in cancer patients.